The 14th annual health event draws nearly 500 healthcare leaders and innovators to the MaRS Centre – industry experts, investors, innovators, and media across digital health, medical devices and biotech – to commercialize new breakthroughs, empower healthcare workers and improve patient outcomes.
MaRS Impact Health is presented in partnership with AstraZeneca, CAI, District3 Innovation, FACIT, Jazz Pharmaceuticals, JLABS, Life Sciences Ontario, Lumira Ventures, MaRS IAF, Medical Innovation Xchange, Mining Innovation Commercialization Accelerator, Novartis, Ontario Bioscience Innovation Organization, Ontario Brain Institute, Synapse Life Science Consortium, Toronto Innovation Acceleration Partners and Velocity.
TORONTO, April 19, 2023 – Today, MaRS announced the program and partners for its annual health innovation event, MaRS Impact Health. The two-day conference features keynotes, panels and pitches from some of the top leaders in healthcare.
“MaRS Impact Health is a two-day showcase of some of Canada’s early-stage health innovation that brings together our ecosystem, content and curated networks to advance health innovators and commercialize their technologies,” says Amol Deshpande, senior director, health sciences at MaRS. “International investors and industry leaders are taking note of Canada’s wide ranging expertise in health science. It’s a critical time to highlight our leadership in key areas such as artificial intelligence, cell and gene therapies and medical devices.”
MaRS Impact Health will take place on May 3 and 4, 2023, at the MaRS Centre in downtown Toronto. It will bring together nearly 100 health experts to the stage, including Jessica Chutter, vice chair and chair of biotechnology investment banking at Morgan Stanley; Brigitte Nolet, CEO of Roche Canada Pharma and Camella Wilson, vice president at Northpond Ventures, to share their vision for building Canada’s health innovation ecosystem.
“Canada is home to a thriving biopharmaceutical sector, including one of the world’s most educated and diverse talent pools and a great network of world-class universities, hospitals and research centres across the country,” says Kiersten Combs, President of AstraZeneca Canada. “As one of Canada’s leading biopharmaceutical companies, AstraZeneca is proud to be a sponsor of MaRS Impact Health – helping to tackle key health care challenges by bringing together leaders in health sciences to spotlight and advance great health innovation in Canada”
MaRS Impact Health’s programming falls into three tracks:
Tickets are $500 until April 30 and include:
MaRS Impact Health attracts nearly 500 health innovation leaders each day. Last year, more than 14 countries and more than 400 organizations were represented.
MaRS Impact Health features the most promising companies and discoveries solving today’s biggest health challenges. Meet the brilliant minds improving healthcare on a global scale: entrepreneurs, investors, academics, clinicians and policymakers.
Learn more and register for MaRS Impact Health 2023 at impacthealth.marsdd.com
For further information: email@example.com